Semaglutide Cuts Cardiovascular Events by 21% in Patients at High Risk of Liver Fibrosis: SELECT Subanalysis

Bottom line: Semaglutide 2.4 mg weekly provides robust cardiovascular protection even — and perhaps especially — in patients whose obesity coexists with markers of significant liver fibrosis.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the incretin hormone GLP-1, enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Originally approved for type 2 diabetes, it is now widely used for weight management and has demonstrated cardiovascular benefits in the landmark SELECT trial.

Background

The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) enrolled over 17,600 patients with established atherosclerotic cardiovascular disease and a BMI ≥ 27, but without diabetes. The primary result — a 20% reduction in three-point MACE (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) — was published previously. This new prespecified secondary analysis, published in Nature Medicine on April 2, 2026, specifically examines outcomes in participants at elevated risk of substantial liver fibrosis.¹

Key Findings

• MACE reduction in high-fibrosis group: Semaglutide reduced three-point MACE by 21% versus placebo (HR 0.79) in patients with elevated FIB-4 scores (≥ 1.3), indicating intermediate-to-high fibrosis risk.¹
• Liver biomarker improvement: Semaglutide significantly lowered ALT, AST, and FIB-4 scores over the study period, suggesting attenuation of hepatic inflammation and fibrosis progression.¹
• Steatosis risk reduction: Hepatic steatosis risk markers also improved, consistent with the known metabolic effects of GLP-1 receptor agonists on liver fat.¹
• Consistency across subgroups: The cardiovascular benefit was consistent regardless of baseline fibrosis risk category, though numerically larger in the high-risk group.¹

Why It Matters

Metabolic dysfunction-associated steatohepatitis (MASH) and cardiovascular disease share obesity and insulin resistance as common drivers. Clinicians managing patients with both conditions have lacked a single intervention addressing both pathways simultaneously. This analysis provides early evidence that semaglutide may fill that gap.

The findings complement the ongoing ESSENCE Phase 3 trial, which is evaluating semaglutide 2.4 mg specifically for biopsy-confirmed MASH with fibrosis. Interim ESSENCE results showed semaglutide achieved histological improvement in steatohepatitis and fibrosis at 72 weeks.

For more on semaglutide's mechanism and clinical uses, see our peptide profile. Related research on GLP-1 receptor agonists and cardiovascular outcomes provides additional context.

Clinical Implication

Prescribers managing obese patients with cardiovascular disease should proactively assess liver fibrosis risk (e.g., FIB-4 index). In those with elevated scores, semaglutide offers a compelling dual benefit — reducing both MACE and hepatic disease progression — making it a strong first-line consideration over GLP-1 RAs lacking equivalent hepatic data.

---

¹ Leung M, et al. Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial. Nature Medicine. Published April 2, 2026. DOI: 10.1038/s41591-026-04281-1